@FierceBiotech: Regulators start thinking creatively about new approval pathway. Report | Follow @FierceBiotech
@JohnCFierce: Troubled Marina Biotech does a DNAi discovery deal with scads of biobucks involved. Release | Follow @JohnCFierce
@RyanMFierce: An interesting skeptic's take on the promise of DNA sequencing personalizing healthcare. Story | Follow @RyanMFierce
@FierceMedDev: Chicago hospital doctors say iPads raise their efficiency, via Fox News. Article | Follow @FierceMedDev
> Elan has raised $381 million from the sale of Alkermes stock. Report
> The FDA has accepted Cornerstone Therapeutics' NDA for a drug that treats hyponatremia, abnormally low blood sodium levels often seen in heart failure patients. The agency set Oct. 29 as the PDUFA date. Story
> BioFocus and Argenta have forged a multi-year collaboration agreement with AstraZeneca to find new compounds for AZ's research programs in respiratory and inflammatory diseases. Release
Pharma News
@FiercePharma: Interesting Bloomberg piece on Austrian who made his millions off drug-price differences in U.K. and EU. Article | Follow @FiercePharma
> Sanofi to shutter Plavix-producing U.K. plant. Item
> Novo seen to benefit from Pfizer-Biocon split. Report
> Judge chooses lead lawyers in Actos litigation. News
> Bayer eyes 16% pharma growth on new meds. Story
> Austrian racks up millions from parallel trade in EU. More
Medical Device News
> Medtronic faces more shareholder ire over Infuse. More
> ViewRay closes $45M Series C. News
> Boston Sci, Vodafone partner on mobile health monitoring. Story
Biomarkers News
> Inflammatory protein marks heart disease. Item
> Researchers find 5 Crohn's disease markers in Ashkenazi Jews. Story
> New biomarkers could mean a blood test for autism. More
> Chikungunya could identify high-risk patients. Article
> Genetic mutation links with age in neuroblastoma. Story
> Nuclea Bio hunts prostate markers. Item
Drug Delivery News
> Kala Pharmaceuticals, co-launched by MIT's Langer, snags $6.2M. News
> InflammaGen drug delivery weapon targets self-digestion in Phase II trial. Article
> Scientists harness molecular 'transporter' to boost drug delivery prowess. Story
And Finally… Investigators at the University of Kentucky say they have gained new insights into developing treatments for triple-negative breast cancer. They add they've found a master switch involved in the spread of cancer cells. Release